Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Endothelial Dysfunction Clinical Trial

Official title: A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 With and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)

Status Active, not recruiting

Clinical Trial Summary

Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually. There is currently no disease-modifying treatment for corneal edema. Topical treatments like hypertonic saline are not effective on a long-term basis. For those with advanced disease, where edema and vision loss are not controlled by topical treatment, the only option is a corneal transplant. A potential approach to avoidance of the risks of corneal transplantation is to inject cultured human corneal endothelial cells (HCECs) into the anterior chamber of the eye. This approach may avoid surgery by re-populating the inner most aspect of the cornea with functioning endothelial cells. Emmecell has developed a treatment based on technology integrating biocompatible magnetic nanoparticles with cultured HCECs to treat corneal edema in a minimally invasive way. The primary objective of this phase 1, prospective, multi-center, open-label, dose-escalation study is to evaluate the safety and tolerability of 3 doses of EO2002 with and without endothelial brushing (EB) or Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK.

Clinical Trial Description

The study is designed to occur in 2 groups. The objective with the first group is to preliminarily evaluate the safety of 4 escalating doses. The purpose of the second group is to gather additional safety information on the 3 highest doses when administered according to a randomized schedule and evaluated by masked observers. Group 1: Phase 1 prospective, multi-center, open-label, dose-escalation study designed to evaluate the safety and tolerability of EO2002 with and without endothelial brushing (EB) or Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK. Four doses will be studied in approximately 21 study participants that meet the inclusion/exclusion criteria. Safety and tolerability will be the primary focus for 26 weeks following treatment with EO2002. Group 2: The three highest doses will be administered to up to 21 subjects in a randomized, double-masked design. ;

Related Conditions & MeSH terms

• Bullous Keratopathy
• Corneal Dystrophies, Hereditary
• Corneal Edema
• Corneal Endothelial Dystrophy
• Edema
• Endothelial Dysfunction
• Fuchs Dystrophy
• Fuchs Endothelial Corneal Dystrophy
• Fuchs' Endothelial Dystrophy
• Pseudophakic Bullous Keratopathy

• NCT number: NCT04894110
• Study type: Interventional
• Source: Emmecell
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: June 22, 2021
• Completion date: October 30, 2024